Explore ViiV Healthcare

I am a
... looking for

ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017

22 abstracts related to HIV treatment and prevention to be presented at major international HIV conference

London UK, 20 July, 2017 ‑ ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting 22 abstracts at the annual conference of the International AIDS Society (IAS) 23–26 July, 2017, Paris, France.

John C. Pottage Jr, Chief Scientific and Medical Officer at ViiV Healthcare, commented: “People living with HIV, and their healthcare providers, continue to look for improvements in areas related to their long-term care, such as tolerability, safety, dosing schedules, drug interactions and convenience. The data we’re sharing at IAS this year demonstrate our R&D focus on patient-centred care, with a clear drive to find new treatment regimens, new ways to deliver HIV treatments and entirely new molecules to treat and prevent HIV.”

While significant progress has been made in tackling the global HIV epidemic, it remains a substantial public health challenge, as 2.1 million people were newly infected in 2014 and more than 36 million people live with HIV worldwide.1 Data to be presented at IAS support ViiV Healthcare’s commitment to delivering advances in treatment and prevention options for people living with HIV (PLWHIV). Key data highlights include:

  • Phase III data comparing a dolutegravir-based regimen against lopinavir/ritonavir-based regimens in patients failing first-line therapy in resource-limited settings (DAWNING)
  • A sub-study of SWORD 1 & 2: effect of switching from TDF-based regimens to dolutegravir and rilpivirine on bone mineral density and bone turnover markers
  • Longer-term (96-week) safety and efficacy data from a phase II study of a long-acting, two-drug regimen including cabotegravir and rilpivirine (LATTE-2)
  • Safety, efficacy and effects on lipid profiles of switching from a boosted protease-inhibitor-based regimen to dolutegravir-based regimen in HIV patients with high CV risk (NEAT 022)
  • Phase II data from a safety and acceptability study of long-acting, injectable, cabotegravir in HIV-uninfected men and women (HPTN 077)
  • Phase II safety and efficacy data for a two-drug regimen of dolutegravir and lamivudine in treatment-naïve patients in high- and low-baseline viral load (ACTG 5353)
  • Results from an international survey of PLWHIV to explore the impact of living with an HIV diagnosis on quality of life, outlook and aspirations

These data cover a wide range of important areas in HIV research, such as:

  • Safety and efficacy in diverse populations including treatment-naïve, treatment-experienced individuals, paediatric patients and women living with HIV who are also pregnant
  • Quantitative and qualitative research into the lives of PLWHIV, and their needs and expectations

The breadth of this research is a result of ViiV Healthcare’s holistic approach to innovation and dedication to advancing options to help lessen the lifetime burden of HIV therapy on the lives of PLWHIV and to reduce the chance of infection altogether.

Accepted Abstracts

Dolutegravir

Abstract Title Lead Author Type Location/ Time
MOPEB0283 Dolutegravir use during pregnancy and birth outcomes: data from the Antiretroviral Pregnancy Registry (APR) V. Vannappagari Poster Exhibition Poster Exhibition Area
Monday, 24 July
MOPEC0609 Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir C. Thorne Poster Exhibition Poster Exhibition Area
Monday, 24 July
MOPEB0287 Dolutegravir-lamivudine as initial therapy in HIV-infected, ARV-naive patients: 96 week results of the PADDLE trial M. I. Figueroa Poster Exhibition Poster Exhibition Area
Monday, 24 July
TUPDB0205LB Sub-study 202094 of SWORD 1 & SWORD 2: switch from TDF-containing regimen to DTG+RPV improves bone mineral density and bone turnover markers over 48 weeks G. McComsey Poster Discussion Abstract Havana Amphitheater
Tuesday, 25 July
13:00  
TUAB0102 Switching from a boosted protease inhibitor (PI/r)-based regimen to a dolutegravir regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years is non-inferior and decreases lipids J. M. Gatell Oral Abstract Le Grand Amphithéâtre
Tuesday 25, July
14:45
TUAB0105LB Superior efficacy of dolutegravir (DTG) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) plus 2 NRTIs in second-line treatment: interim data from the DAWNING study M. Aboud Oral Abstract Le Grand Amphithéâtre
Tuesday 25, July
15:45
MOAB0103 ACTG A5353: a pilot study of dolutegravir (DTG) + lamivudine (3TC) for initial treatment of HIV-1-infected participants with HIV-1 RNA <500,000 copies/mL B. O. Taiwo Oral Abstract Le Grand Amphithéâtre
Monday, 24 July
11:30
WEPEB0573 Initial regimen duration in female patients taking integrase strand transfer inhibitors (INSTI) in the OPERA® observational database F. Carpio Poster Exhibition Poster Exhibition Area
Wednesday, 26 July

Cabotegravir

Abstract Title Lead Author Type Location/Time
MOAX0205LB Safety and efficacy of long-acting CAB and RPV as two-drug IM maintenance therapy: LATTE-2 week 96 results J. Eron Oral Abstract Blue Amphitheater
Monday, 24 July
12:00
TUAC0106LB Safety, tolerability and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected women and men: HPTN 077 R. Landovitz Oral Abstract Blue Amphitheater
Tuesday, 25 July
12:15

Fostemsavir

Abstract Title Lead Author Type Location/Time
MOPEB0339
The effect of fostemsavir on the pharmacokinetics of a combined oral contraceptive (OC) containing ethinyl estradiol (EE) and norethindrone (NE) in healthy female subjects M. Magee Poster Exhibition
Poster Exhibition Area
Monday, 24 July
MOPEB0338
The effect of fostemsavir on methadone and buprenorphine pharmacokinetics
H. Sevinsky
Poster Exhibition
Poster Exhibition Area
Monday, 24 July

Abacavir

Abstract Title Lead Author Type Location/Time
WEPEB0542
Uptake of HLA-B*5701 screening and its impact on clinically suspected hypersensitivity reaction to abacavir in the OPERA® Observational Database
K. Mounzer
Poster Exhibition
Poster Exhibition Area
Wednesday, 26 July

Maraviroc

Abstract Title Lead Author Type Location/Time
TUPEB0435
Longer-term safety of maraviroc in paediatric patients with R5 HIV: follow-up data from study A4001031
C. Giaquinto
Poster Exhibition
Poster Exhibition Area
Tuesday, 25 July
TUPEB0433
Maraviroc pharmacokinetics and dosing recommendations in CCR5-tropic HIV-1-infected children aged 2 to <18 years
M. Vourvahis Poster Exhibition
Poster Exhibition Area
Tuesday, 25 July
TUPEB0432 Pharmacokinetic (PK) modelling and simulation to support weight-based dosing of maraviroc (MVC) in paediatric subjects when co-administered with potent CYP3A inhibitors L. McFadyen Poster Exhibition Poster Exhibition Area
Tuesday, 25 July

GSK3532795/BMS-955176

Abstract Title Lead Author Type Location/Time
MOPEB0347
Resistance profile of GSK3532795
I. Dicker Poster Exhibition
Poster Exhibition Area
Monday, 24 July
TULBPEB21
Safety, efficacy, and dose-response of GSK3532795/BMS-955176 plus tenofovir/emtricitabine (TDF/FTC) in treatment-naïve (TN) HIV-1-infected adults: week 24 primary analysis J. Morales-Ramirez
Poster Exhibition
Poster Exhibition Area
Tuesday, 25 July
WEPEB0540
An analysis of neurologic and psychiatric adverse events of subjects receiving the investigational HIV-1 maturation inhibitor (MI) GSK3532795/BMS-955176 J. Gan Poster Exhibition Poster Exhibition Area
Wednesday, 26 July

Other/Non-Product Related

Abstract Title Lead Author Type Location/Time
MOPEB0274
Atypical mutations for RAL resistant clinical isolates, and associated integrase strand transfer inhibitor susceptibility with public algorithms
M. Underwood
Poster Exhibition
Poster Exhibition Area
Monday, 24 July
WEPED1423
Experience of living with HIV: diagnosis & disclosure - findings from the Positive Perspectives study A. Murungi Poster Exhibition
Poster Exhibition Area
Monday, 24 July
WEAA0203
Inhibiting memory CD4+ T-cell self-renewal to reduce HIV persistence M. Mavigner Oral Abstract
Maillot Room
Wednesday, 26 July
17:00

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined in October 2012. The company’s aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com

About GSK

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Contacts:

ViiV Healthcare Media enquiries: Sébastien Desprez (on site at IAS)   +44 (0) 20 8380 6275
  Marc Meachem (on site at IAS)   +1 919 483 8756
  Patricia O’Connor +44 (0) 208 047 5982
GSK Global Media enquiries: David Daley +44 (0) 20 8047 2615
  Kathleen Cuca +1 215 859 1922
GSK US Media enquiries: Mary Anne Rhyne +1 919 483 0492
  Sarah Spencer +1 215 751 3335
Analyst/investor enquiries: Sarah Elton-Farr +44 (0) 20 8047 5194
  Gary Davies +44 (0) 20 8047 5503
  James Dodwell +44 (0) 20 8047 2406
  Sarah Webster +44 (0) 20 8047 0246
  Tom Curry +1 215 751 5419
  Jeff McLaughlin +1 215 751 7002

REFERENCES

1. UNAIDS. Fact Sheet. Available at: http://www.unaids.org/en/resources/fact-sheet Last accessed July 2017

Website images are not intended to imply that the models pictured have HIV.